Latest news with #NasdaqGS
Business Wire
40 minutes ago
- Business
- Business Wire
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
3 hours ago
- Business
- Yahoo
Western New England Bancorp, Inc. Announces Completion of 2024 Repurchase Plan
WESTFIELD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Western New England Bancorp, Inc. (the 'Company' or 'WNEB') (NasdaqGS: WNEB), the holding company for Westfield Bank (the 'Bank'), announced that on May 30, 2025, the Company completed all repurchases under its existing stock repurchase plan (the '2024 Repurchase Plan') at an average price per share of $8.79. The 2024 Repurchase Plan authorized the Company to repurchase a total of 1.0 million shares of the Company's common stock, or approximately 4.6% of the Company's then-outstanding shares of common stock. The Board of Directors authorized the 2024 Repurchase Plan on May 21, 2024. On April 22, 2025, the Board of Directors of the Company authorized a new stock repurchase plan, pursuant to which the Company may repurchase up to 1.0 million shares, or approximately 4.8% of the Company's outstanding shares of common stock, upon the completion of the 2024 Repurchase Plan. James C. Hagan, President and Chief Executive Officer, commented, 'We are pleased to announce the completion of our 2024 Repurchase Plan. We believe that share repurchases are a prudent use of the Company's capital and demonstrate our commitment to effectively manage the Company's capital levels, while increasing total shareholder returns through stock repurchases as well as cash dividends.' The Company may repurchase shares from time to time in open market transactions or through privately negotiated transactions at the Company's discretion or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The amount, timing and nature of any share repurchases will be based on a variety of factors, including the trading price of the Company's common stock, applicable securities laws restrictions, regulatory limitations and market and economic factors. The repurchase program may be modified, suspended or discontinued at any time, at the Company's discretion. About Western New England Bancorp, Inc. Western New England Bancorp, Inc. is a Massachusetts-chartered stock holding company and the parent company of Westfield Bank, CSB Colts, Inc., Elm Street Securities Corporation, WFD Securities, Inc. and WB Real Estate Holdings, LLC. Western New England Bancorp, Inc. and its subsidiaries are headquartered in Westfield, Massachusetts and operate 25 banking offices throughout western Massachusetts and northern Connecticut. To learn more, visit our website at Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Company's financial condition, liquidity, results of operations, future performance, and business. Forward-looking statements may be identified by the use of such words as 'believe,' 'expect,' 'anticipate,' 'should,' 'planned,' 'estimated,' and 'potential.' Examples of forward-looking statements include, but are not limited to, estimates with respect to our financial condition, results of operations and business that are subject to various factors which could cause actual results to differ materially from these estimates. Although we believe that the expectations reflected in such forward-looking statements are reasonable, actual results may differ materially from the results discussed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed under the caption 'Risk Factors' in Western New England Bancorp's Annual Report on Form 10-K for the year ended December 31, 2024 and in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. We do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except to the extent required by law. For further information contact:James C. Hagan, President and Chief Executive OfficerGuida R. Sajdak, Executive Vice President and Chief Financial OfficerMeghan Hibner, First Vice President and Investor Relations Officer413-568-1911
Yahoo
4 hours ago
- Business
- Yahoo
BioNTech (NasdaqGS:BNTX) Enters Global Co-Development Agreement With Bristol Myers Squibb
BioNTech has seen a significant price movement in the past week, with its stock rising by 15%, compared to a 2% increase in the broader market. The recent co-development and co-commercialization agreement between BioNTech and Bristol Myers Squibb for the bispecific antibody BNT327 may have supported this upswing. Additionally, the anticipation surrounding BioNTech's presentations at the ASCO Annual Meeting, showcasing promising clinical trial data, possibly added weight to the positive sentiment. While the market has performed well, these focused developments in BioNTech's oncology pipeline likely provided an additional boost. Buy, Hold or Sell BioNTech? View our complete analysis and fair value estimate and you decide. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. The co-development agreement between BioNTech and Bristol Myers Squibb for the bispecific antibody BNT327, alongside BioNTech's presentations at the ASCO Annual Meeting, could significantly impact its revenue and earnings forecasts. The collaboration and new clinical data may enhance BioNTech's oncology portfolio, potentially driving revenue growth from innovative treatments and first-in-class approvals. Despite this, high R&D expenses and dependency on COVID-19 vaccine sales remain critical risks that could affect financial stability if not offset by new product launches. Over a five-year period, BioNTech has achieved a total return of 134.10%, indicating strong longer-term appreciation. This contrasts with the past year's performance, where the company outperformed the US Biotech industry, which experienced a decline of 13.1%. Despite this favorable long-term total return, the current share price, having climbed 15% recently, still falls short of analyst price targets, suggesting a potential growth opportunity if analyst expectations for the stock materialize. The valuation report we've compiled suggests that BioNTech's current price could be inflated. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:BNTX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Business
- Yahoo
Costamare Joins Two Strong Dividend Stocks For Your Portfolio
Over the last 7 days, the United States market has risen by 2.0%, contributing to a 12% increase over the past year, with earnings forecasted to grow by 14% annually. In this favorable market environment, selecting dividend stocks like Costamare and two other strong performers can be an effective strategy for investors seeking steady income and potential growth. Name Dividend Yield Dividend Rating Columbia Banking System (NasdaqGS:COLB) 6.25% ★★★★★★ First Interstate BancSystem (NasdaqGS:FIBK) 7.03% ★★★★★★ Dillard's (NYSE:DDS) 6.64% ★★★★★★ Ennis (NYSE:EBF) 5.41% ★★★★★★ Chevron (NYSE:CVX) 4.96% ★★★★★★ CompX International (NYSEAM:CIX) 4.82% ★★★★★★ Universal (NYSE:UVV) 4.96% ★★★★★★ Credicorp (NYSE:BAP) 5.15% ★★★★★☆ Southside Bancshares (NYSE:SBSI) 5.18% ★★★★★☆ Huntington Bancshares (NasdaqGS:HBAN) 3.98% ★★★★★☆ Click here to see the full list of 147 stocks from our Top US Dividend Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Costamare Inc. is a global owner and operator of containerships and dry bulk vessels, with a market cap of approximately $1.03 billion. Operations: Costamare Inc.'s revenue is primarily derived from its Container Vessels segment, generating $866.17 million, followed by the Dry Bulk Vessels segment with $190.41 million and CBI contributing $996.36 million. Dividend Yield: 5.3% Costamare Inc. offers a dividend yield in the top 25% of US payers, supported by low payout ratios from earnings (18.9%) and cash flows (18.4%). However, its dividend history is marked by volatility and declines over the past decade, raising concerns about reliability. The recent spin-off of its dry bulk business could impact future distributions. Despite trading below estimated fair value, high debt levels may pose risks to sustained dividend payouts. Take a closer look at Costamare's potential here in our dividend report. The analysis detailed in our Costamare valuation report hints at an deflated share price compared to its estimated value. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Global Ship Lease, Inc. operates by owning and chartering containerships under fixed-rate charters to container shipping companies globally, with a market cap of approximately $884.97 million. Operations: Global Ship Lease generates revenue of $715.23 million from its transportation and shipping segment by chartering containerships under fixed-rate agreements to container shipping companies worldwide. Dividend Yield: 8.4% Global Ship Lease's dividend yield ranks in the top 25% of US payers, with a payout ratio of 17.7% from earnings and 59.3% from cash flows, indicating strong coverage. Recent increases include a quarterly dividend of US$0.525 per share, reflecting a substantial rise since last year. Despite trading at good value compared to peers and industry standards, its dividend history has been marked by volatility and declines over the past decade, affecting reliability perceptions. Navigate through the intricacies of Global Ship Lease with our comprehensive dividend report here. According our valuation report, there's an indication that Global Ship Lease's share price might be on the cheaper side. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Safe Bulkers, Inc., along with its subsidiaries, offers international marine drybulk transportation services and has a market cap of $388.78 million. Operations: Safe Bulkers, Inc. generates revenue from its marine drybulk transportation services, with the Transportation - Shipping segment contributing $290.31 million. Dividend Yield: 5.3% Safe Bulkers offers a dividend yield in the top 25% of US payers but lacks free cash flow coverage, raising sustainability concerns. While dividends are covered by earnings due to a low payout ratio, they've been volatile over the past decade. Recent financials show declining revenue and net income, impacting dividend reliability. A recent share buyback of $10.72 million was completed, and dividends were affirmed at $0.05 per share for common stockholders payable in June 2025. Get an in-depth perspective on Safe Bulkers' performance by reading our dividend report here. Our valuation report here indicates Safe Bulkers may be undervalued. Explore the 147 names from our Top US Dividend Stocks screener here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:CMRE NYSE:GSL and NYSE:SB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
6 hours ago
- Business
- Yahoo
Advanced Micro Devices (NasdaqGS:AMD) Powers Rubrik's AI-Ready Data Security Platform Expansion
The integration of AMD EPYC processors into Rubrik's platform exemplifies a recent push for enhanced cost-effectiveness and AI capabilities among enterprise clients. Over the past month, Advanced Micro Devices experienced a price move of 16%, aligning with several influential corporate events. The earnings report on May 6 highlighted strong financial performance with significant sales and net income growth. Additionally, the announcement of a substantial increase in its equity buyback plan on May 14 likely added confidence among investors. These developments potentially provided momentum to AMD's share price, exceeding the market's broader 2% climb last week. Buy, Hold or Sell Advanced Micro Devices? View our complete analysis and fair value estimate and you decide. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. The recent integration of AMD EPYC processors into Rubrik's platform highlights AMD's strategic push to enhance its competitiveness in AI and enterprise markets. Despite this, regulatory challenges and competition are expected to limit AMD's access to key international markets, impacting revenue opportunities. Nevertheless, over the last five years, AMD's total shareholder return was 116.41%. This significant growth contrasts with its 1-year underperformance against the US Semiconductor industry, where it lagged with an 11.6% change. Looking ahead, the recent developments boost investor confidence with potential positive effects on AMD's earnings forecasts, particularly through expanded share in server CPUs and AI-driven demand. While the recent 16% share price movement reflects some immediate investor optimism, it remains below the consensus price target of US$127.53, suggesting room for potential appreciation. It's important to weigh these optimistic growth drivers against the bearish analyst sentiment, which sets a lower price target of US$76.7, recognizing risks such as increased competition and regulatory constraints. As AMD's forward-looking strategies unfold, investor attention will likely remain focused on execution and market conditions affecting its valuation. Gain insights into Advanced Micro Devices' past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:AMD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
